Benitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Development for Oculopharyngeal Muscular Dystrophy (OPMD)

Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference

Benitec Biopharma Announces Acceptance of Late- Breaking Abstract for the BB-301 Phase 1b/2a Clinical Treatment Study at the Muscular Dystrophy Association Clinical & Scientific Conference

Here's Why We're Not At All Concerned With Benitec Biopharma's (NASDAQ:BNTC) Cash Burn Situation

Benitec Biopharma Releases Second Quarter 2026 Financial Results and Provides Operational Update

Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response

Does Benitec Biopharma (BNTC) Have the Potential to Rally 83.87% as Wall Street Analysts Expect?

Wall Street Analysts Predict an 87.48% Upside in Benitec Biopharma (BNTC): Here's What You Should Know

Down 25.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Benitec Biopharma (BNTC)

Citizens Lifts Benitec Biopharma Inc. (BNTC) Price Target on Topline Results for Oculopharyngeal Muscular Dystrophy Treatment